chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm pain; chills; tiredness; This spontaneous case was reported by a patient and describes the occurrence of MYALGIA (arm pain), CHILLS (chills) and FATIGUE (tiredness) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 02A21A) for COVID-19 vaccination.     No medical history was reported by the reporter.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Mar-2021, the patient experienced MYALGIA (arm pain), CHILLS (chills) and FATIGUE (tiredness). The patient was treated with PARACETAMOL (TYLENOL) at a dose of PO BID for 5 days and IBUPROFEN at a dose of 800 mg as required. At the time of the report, MYALGIA (arm pain), CHILLS (chills) and FATIGUE (tiredness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-May-2021, COVID-19: positive.         This case was linked to MOD-2021-154871 (Patient Link).
24 hours after receiving vaccine patient started to experience flu-like symptoms, chills, congestion, coughing, sneezing, and muscle soreness. Patient has not had 14 days of time to develop proper antibody response. Patient tested positive in December of 2020. Patient recently traveled to Pakistan and is going to go get a rapid test to verify if he is re-infected with COVID.
Soreness in arm where shot was administered. Experiencing same level of soreness on day 4 as it was on day 1.
Severe shaking chills, low grade fever, mild headache, night sweats, dry mouth, weakness and low energy, slight dizziness,
(1) Hepatitis A #2 given early; 1st dose 7/28/08 - 2nd dose given 8/26/08; (2) GARDASIL #3 given too early; #1 given 6/24/07, #2 given 7/28/08, #3 given 8/27/08
Pt developed hives/evoking into EM rash within 24 hours of FLUMIST. Treated with HYDROXYZINE and PREDNISONE.
When I had the first shot a month ago the site was just red. I had the 2nd shot yesterday and the spot turned red again and I had a slight headache. I woke up this morning and the spot is red and bubbly and a little warm and it only hurts at that spot.  I went back to Cvs today and asked them to look at it, they said they believe it to be an allergic reaction and I was to submit a report. They said the redness has a lump in it and it is blistering. They said they think it to be a local allergy since it hasn't spread anywhere yet. They told me to take benadryl for it and I could put cream on it, which I did when I got home. They told me to watch for other adverse effects and if I had any I was to go to the er. So far no other reactions but the blistery rash
The patient is a 12 year, 0 month old male who presents with vaccine allergy. Prior to the reaction the patient received HPV vaccine and inactivated influenza vaccine. Allergenic triggers include an unknown source. Presentation included injection site reaction. This problem has not been previously evaluated. This problem has not been previously treated. The last clinic visit was 1 day(s) ago. Symptoms included rash, swelling, warmth and pain. The reaction is located on the left upper extremity. The patient describes the pain as aching. Onset was gradual. Onset followed a vaccination. The patient describes this as moderate in severity. Associated symptoms do not include malaise, irritability, drowsiness, arthralgias, myalgias, anorexia, nausea, vomiting, diarrhea, lightheadedness, palpitations, chest pain or syncope. The patient is not currently being treated for this problem. Note for "Vaccine allergy": Two to four hours after admin of the vaccine, noticed heat, soreness, redness was about the size of a half dollar yesterday, this morning during school it progressed in size. Has been putting ice pack on it. Around 9 am, he saw school nurse. Did not have a temperature of fever. Put an ice pack on it. No fevers or vomiting or difficulty breathing but has a mild stomach ache, thinks it is something he ate at lunch today. Otherwise good energy, appetite, urination and bowel movements are WNL. Pain starts when he moves it, with writing, touching it. Feels like a sore muscle and a little itchy at the top. Still feels very hot. Phone Note 9-30-2016: Received the HPV and flu vaccine yesterday. In the past, he developed cellulitis to one of his arms where he received a vaccine. The area is swollen and red. Mom drew a circle to the reddened area and the redness has now spread beyond the marking. He is having pain to his arm. No fever. Still able to move his arm. He is at school now and called mom c/o pain. Plan: appt.
headaches; swollen eyes; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer reported for a female patient. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number was not re-ported), via an unspecified route of administration on an unspecified date as a dose number un-known, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced headaches and swollen eyes both on an unspecified date. It was reported that, the Reporter's wife experienced headaches and swollen eyes after the vaccine and he was asking if that was normal side effects. The outcome of both the events were unknown.  Follow-up attempts are completed. No further information is expected.
blood sugar high; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of BLOOD GLUCOSE INCREASED (blood sugar high) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BLOOD GLUCOSE INCREASED (blood sugar high). At the time of the report, BLOOD GLUCOSE INCREASED (blood sugar high) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: high (High) high.         No concomitant medications were reported.  No treatment details were reported.
Mild sore and pain at vaccinated area starting around 2:30pm, and I was vaccinated at 12:05pm. Symptoms continued till the night of the second day. Mild fatigue on second day and I went to sleep two times during the day. Mild soreness throughout whole body, especially my back waist, on the second day. It felt like a did crazy snow digging the day before without any warm-up.   All symptoms were gone the third day when I woke up.
Vertigo, ear congestion in right ear with pain,  and non stop bilaterial tinnitus. Also canker sores in mouth.   Ear test negative but increased pressuure in righy ear estatian tube. Tinnitus has not gone away and has varying volume based on the day.
Swelling and erythema on vaccination site, 6cm. After 24 hours vaccine.  Treatment Tylenol or motrin and cold compresses.
mild headache; This is a spontaneous report from a contactable nurse (patient).  This 35-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot GJ1685), via an unspecified route of administration, on 22Dec2020 (reported also as 23Dec2020, to be clarified) at 3:00 PM at single dose for COVID-19 immunisation. Vaccine location was left arm. The patient was vaccinated at Nursing Home/Senior Living Facility, age at vaccination was 35-years-old. No other vaccine was received in four weeks. Medical history and concomitant medications were unknown. On 22Dec2020 at 07:00 PM, the patient got mild headache. The event was reported as non-serious. The patient was tested for Covid post vaccination through a nasal swab in Dec2020 and was negative. Outcome was recovered on Dec2020. No treatment was received for the event.
Information has been received from a registered nurse concerning a patient at an elementary school who was vaccinated with a dose of varicella virus vaccine live. Subsequently the patient developed a case of breakthrough varicella with greater than 50 lesions. It was reported that the cases may be classified as serious because there were more than 50 lesions. There was no product quality complain involved.  Additional information was sought from the school nurse. However, a receptionist indicated that the reporting nurse did not work during the summer while school was out.  Breakthrough varicella was considered to be an other important medical event.   No further details were provided.
Within minutes of receiving the vaccines, pt. became dizzy, lightheaded, pale, she then started mumbling when talking, her eyes rolled back then she fainted. Within seconds of fainting, pt. began to shake violently. She was observed by a doctor who came into the room after the event. She was out for a few minutes before waking up. She wasn't making any sense when talking.
Generalized urticaria & lethargy 15 min after vaccines. Rx BENADRYL, SC epi, and 1 dose prednisolone. Resolution in about 45 minutes.
Patient is a 72 y.o. male who presented to emergency department with complaints of generalized weakness.  He has a past medical history of Alzheimer's dementia- end stage, chronic obstructive pulmonary disease, mutation of bilateral arms below the elbow, and prosthetic left eye. Patient presented with complaints of generalized weakness.  At baseline, he does have dementia which limits assessment ability.  Per his daughter, he has had multiple falls recently.  She states that he ambulates independently, however, very slowly.  Upon examination, patient has no specific complaints.  Patient's daughter has concerns that his wife, who is his primary caregiver is unable to care for the patient because she herself has COVID-19.  In the emergency department, patient's vital signs were stable.  He did not require supplemental oxygen.  Complete blood count and BMP were unremarkable.  COVID-19 was positive.  EKG shows normal sinus rhythm.  CT scan of the head showed chronic maxillary sinusitis and chronic generalized brain atrophy.  CT of the chest showed no acute abnormalities.  Suspect generalized weakness secondary to COVID-19.  Patient has been transferred and admitted to Hospital further evaluation management of generalized weakness.   Patient was evaluated and qualified for monoclonal antibodies. Patient's daughter was at bedside and reported ability to care for patient 24/7 until spouse was able to continue normal care. Risk and benefits discussed with daughter who agreed upon infusion and discharge home when safe. Patient received therapy without interactions.    The patient was evaluated by PT and OT, both therapists recommended subacute rehab and a walker for home use. This was discussed with the patient and daughter; the daughter plans to bring him to her home with 24 hour care until his wife (primary caregiver) is recovered from COVID infection.  The patient continues on room air, he has some fatigue, but is otherwise stable.  The patient will be discharged in the care of his daughter until he can return home.
Hives near injection site and on injection site extremity (left arm) onset at approximately 3 hours post injection. Itching, and generalized pain within 12 inches of injection site onset approximately 2.5 hours post injection. Was unable to raise arm above 45 degrees, related to pain and discomfort. Applied anti inflammatory cream to effected extremity and tool 50 mg benedryl, reduction in hives and itching noted in 30 minutes. Pain continued for approximately 18 hours at 6-8 on 10 scale and then reduced to 3/10 scale. Difficulty sleeping noted.
Discharge Provider: MD  Primary Care Provider : DO  Admitting Service: Internal Medicine Service Admission Date: 12/24/2022 Discharge Date: 12/29/2022 COVID positive Date 12/24/2022 PRESENTING PROBLEM:  Acute respiratory failure with hypoxia [J96.01] Hypothermia, initial encounter [T68.XXXA] Acute on chronic respiratory failure with hypoxia and hypercapnia [J96.21, J96.22] Sepsis, due to unspecified organism, unspecified whether acute organ dysfunction present [A41.9] COVID-19 [U07.1] Bacteremia [R78.81]   HOSPITAL COURSE:   82 year old female with paroxysmal atrial fib, ESRD (on HD TIW via AVF), and HTN presented for SOB after having URI symptoms several weeks ago and missing HD run 12/23 per granddaughter.  While being evaluated by EMS went apneic (no loss of pulses).  She was bagged in transit and intubated in the ED.  COVID-19 was (+) (vaccinated X3, overdue for booster, was COVID+ in October).  CXR showed diffuse opacities, VBG 6.9/>100, lactate 4.4, BNP 6k.  She was given Zosyn / Vanco / Decadron.  Following intubation, required NE.  TTE showed EF 30% with severe global hypokinesis.  NE was exchanged for Epi gtt.  She was seen by cardiology with recommended followup TTE when clincally improved.  She recieved IHD run 12/24 and tolerated removal of 1.5Ls.  She weaned off Epi 12/25.  Blood cultures from admission were (+) 2:2 for strept - mitis / oralis identified (followup 12/25 NGTD).  ID was consulted.  Her respiratory status improved and she was extubated 12/25, oxygen requirement significantly improved, eventually did not require any oxygen, repeat blood cultures remained negative since 12/25.  Cardiology recommended initiating goal-directed medical therapy, she was started on low-dose Coreg and Entresto, outpatient follow-up with Cardiology was recommended.  Infectious Disease recommended continuing ceftriaxone inpatient in transition to amoxicillin 1 g daily to complete total 14 days, PT and OT did not recommend any skilled therapy.  Doing well discharge home in stable condition, recommended follow-up with PCP in 1 week, instructions discussed in detail with patient who verbalized understanding.
Very mild soreness at the injection site when touched; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). This consumer reported similar events for two patients. This is 1 of two reports.   A female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm left, administration date 11Mar2021 (Lot number: En6204, Expiration Date: Jun2021) as dose 2, single for COVID-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162B2 (dose number=1, Lot number=En6201, expiry date: Jun2021, administration time=11:00 AM, vaccine location=Left arm), administration date: 18Feb2021, for COVID-19 immunization. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 11Mar2021 11:00, outcome "unknown", described as "Very mild soreness at the injection site when touched". Therapeutic measures were not taken as a result of vaccination site pain.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021275482 same reporter, drug and event, different patient
No adverse event; may not have completed a primary vaccination series prior to receiving the bivalent product; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may not have completed a primary vaccination series prior to receiving the bivalent product) and NO ADVERSE EVENT (No adverse event) in a 39-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7145B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Sep-2022, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 08-Sep-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may not have completed a primary vaccination series prior to receiving the bivalent product). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may not have completed a primary vaccination series prior to receiving the bivalent product) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may not have completed a primary vaccination series prior to receiving the bivalent product).    No concomitant medications were reported.  It was reported that patient received the first dose of the Moderna COVID-19 vaccine by intramuscular injection on 8-Feb-2022 (lot number 083J21A, expiration date 3-May-2022, monovalent product).  It was reported that patient had not reported any symptoms. No additional doses, medications had been administered at this time.  No treatment medications were reported.
wrong dose was given- patient received 0.5ml dose instead of 0.25ml dose
Developed fever of 100 last night and had left sided abd pain on Wednesday.  8/26/09.  Woke up this AM 8/27/09 with rash on back of legs and waist that itch.  Today has sore throat and some sinus congestion, some nausea.  Strept screen negative.  Given topical cream and XYZAL for itching.
A temperature of 105F (axillary) noted in the evening, post vax. Antipyretic give and pt was seen in an ER. No physical findings or associated symptoms were present. Symptomatic care was recommended. Fever is present still, on 1/7/02. Pharyngitis was noted on 1/7/02.
Face became numb; Lips began to swell; Her bottom lips was burning; Throat was scratchy; Ice tea burn as it was going down; Coughing; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 01-Mar-2021 and was forwarded to Moderna on 01-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Face became numb), LIP SWELLING (Lips began to swell), ORAL DISCOMFORT (Her bottom lips was burning), OROPHARYNGEAL DISCOMFORT (Throat was scratchy) and ORAL DISCOMFORT (Ice tea burn as it was going down) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001AZIA) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma and Shellfish allergy.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, the patient experienced HYPOAESTHESIA (Face became numb), LIP SWELLING (Lips began to swell), ORAL DISCOMFORT (Her bottom lips was burning), OROPHARYNGEAL DISCOMFORT (Throat was scratchy), ORAL DISCOMFORT (Ice tea burn as it was going down) and COUGH (Coughing). At the time of the report, HYPOAESTHESIA (Face became numb), LIP SWELLING (Lips began to swell), ORAL DISCOMFORT (Her bottom lips was burning), OROPHARYNGEAL DISCOMFORT (Throat was scratchy), ORAL DISCOMFORT (Ice tea burn as it was going down) and COUGH (Coughing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
Soreness at injection site: beginning at approx. 8:15 PM through present Soreness when lifting left arm: 3/25-3/27 Chills: beginning approx. 4:25 AM - 10:00 PM, 3/25 Severe headache: pain at top of head, temples, cheeks and jaw line: beginning approx. 9:00 PM, 3/25, through 2:30 PM, 3/26
Approx 40 hrs after injection, blurred vision, two hrs later, vision was restored to about 80%, one hr after that, blurred vision returned, restored two hours after onset to about 90%, then blurred vision returned for 2 more hours and. Restored to 100%.  All total episode lasted 5 hours.
Received 5 Covid-19 vaccinations/contracting Covid; Received 5 Covid-19 vaccinations/contracting Covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  An 85-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Received 5 Covid-19 vaccinations/contracting Covid". He has received 5 Covid-19 vaccinations in which the last one was in Nov. He stated the vaccines were a mixture; however they, were "mostly from Pfizer and the other one started with a S. Therapeutic measures were taken as a result of drug ineffective, covid-19: he was prescribed Paxlovid two days ago due to contracting Covid.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.
Guillain Barre syndrome - treated with IVIG - undergoing PT/OT; still hospitalized
Patient?s lips and eyes swelled.She reported tingly lips, felt shaky. EMT took BP was136/74. She was observed by MD over one hour. She was assessed as no longer having swelling and reported feeling better. She planned to go home and take benedryl.
Lost vision in left eye for 1 month. I had extreme pain of which I had to take pain medication, several eye drops and oral prednisone. Missed 1 month of work as a registered nurse and filed for state disability at that time. Saw several doctors. After extensive testing, they concluded I am HLAB-27 Positive. This test result coincides with paneuveitis which is what I had. The doctors dismissed that this reaction was related to a flu vaccine.
6/14 79y.o. female with a medical history significant for Dementia, patient is nonverbal, hyperlipidemia, hypertension.  Patient currently admitted with progressive harsh cough and worsening of altered mental status with coronavirus concern.
I am experiencing pain in my shoulder where I got the shot; This is a spontaneous report from a contactable consumer (the patient).   A 9-decade-old patient of an unspecified gender received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on 19Aug2021 (Batch/Lot Number: EW0181) as single dose  for covid-19 immunisation  .  Medical history included anticoagulant therapy.  The patient's concomitant medications were not reported.  The patient experienced pain in my shoulder where i got the shot  (non-serious) on 19Aug2021 with outcome of unknown. The patient still has pain in the muscle three days after the shot.  Follow up information has been requested.
Diarrhea, bloating, gastrointestinal cramping, fatigue, nausea for 48 hours and then again for 24 hours with 24 hours in between of feeling better